# Transcode Therapeutics, Inc. — Form D

Transcode Therapeutics, Inc. of BOSTON, MA, a company, filed a Form D exempt-offering notice with the SEC on 2024-12-12. The offering totals $8.0M, of which $8.0M was reported sold. Industry: Biotechnology.

## Offering

- Filed: 2024-12-12
- Form: D
- Accession: 0001104659-24-128019
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $8.0M
- Amount sold: $8.0M
- Investors: 6
- Date of first sale: 2024-12-02
- Security types: equity
- Revenue range: No Revenues
- SEC file number: 021-531946

## Issuer

- Name: Transcode Therapeutics, Inc.
- CIK: 0001829635
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Address: 6 LIBERTY SQUARE, #2382, BOSTON, MA, 02109
- Phone: 857-837-3099

## Officers, directors & promoters (5)

| Name | Role | Location |
| --- | --- | --- |
| Philippe A Calais | Director | Boston, MA |
| Thomas A Fitzgerald | Director | Watertown, MA |
| Erik A Manting | Director | Boston, MA |
| Magda A Marquet | Director | Boston, MA |
| Thomas A Fitzgerald | Executive Officer | Watertown, MA |

## More

- [CIK 1829635 on SEC EDGAR (source of record)](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1829635&type=&dateb=&owner=include&count=40)
- [This page as markdown (for LLM agents)](https://search.stillhousedata.com/formd/0001104659-24-128019.md)
- [Search all SEC filings, advisers and people on Adviser Search](https://search.stillhousedata.com/)

---

Source: public SEC filing data via Adviser Search (https://search.stillhousedata.com).
Agents: this data is also queryable via MCP tools and read-only SQL — see https://search.stillhousedata.com/llms.txt.